In Brief

Watson adds Actavis for $5.6 bil.; Recordati buys OTCs in Germany; DoJ weighs in on Plan B case; NARC rebranded as ASRC; Korean lawmakers miss another chance on OTC bill; more news In Brief.

Allergan PLC becomes the world’s third-largest generics firm with its $5.60 billion acquisition of Iceland-based Actavis, announced April 25. The deal will expand substantially Watson’s global reach; once it closes, 40% of the Parsippany, N.J., company’s revenues will come from outside the U.S., compared to 16% now. Actavis’ portfolio has more than 830 generic products, and its U.S. subsidiary in Morristown, N.J., manufactures OTCs including bacitracin zinc ointment and children’s ibuprofen oral suspension. Watson is restructuring its leadership to support the Actavis addition. Among the personnel moves, Sigurdur Oli Olafsson, executive VP of global generics, is named president of global generics April 27.

Recordati S.p.A. adds six OTC brands to its portfolio with acquisitions from Johnson & Johnsonsubsidiaries Cilag GmbH and McNeil...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Distribution/Supply Chain

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

EUCOPE Wants Simpler Manufacturing Rules And Framework For Combined Trials Under EU Biotech Act

 

EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.

More from Compliance

EUCOPE Wants Simpler Manufacturing Rules And Framework For Combined Trials Under EU Biotech Act

 

EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.

UK MHRA Helps Sponsors Prepare For ‘World’s First’ Decentralized Manufacturing Framework

 

The UK drug regulator, the MHRA, is set to launch its decentralized manufacturing framework in July, and has issued a series of guidance documents that it believes will help companies and also be of value to other countries that are considering how best to regulate the fledging sector.

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By 

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.